AI Sharpens Lung Cancer Response Assessment

Why pathological response matters

For patients with resectable (NSCLC), neoadjuvant chemoimmunotherapy is increasingly used before surgery. Assessing how much viable tumour remains after treatment can provide an important indication of therapeutic response. Pathological response is commonly expressed as the percentage of residual viable tumour (%RVT). Major pathological response (MPR) is defined as ≤10% RVT in the primary tumour, while pathological complete response (pCR) requires no viable tumour in either the primary tumour or lymph nodes.